{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:10:08Z","timestamp":1791987008143,"version":"4.4.0"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T00:00:00Z","timestamp":1542240000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671622"],"award-info":[{"award-number":["81671622"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81701621"],"award-info":[{"award-number":["81701621"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02663","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T06:48:52Z","timestamp":1542264532000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Interleukin-33 in Systemic Sclerosis: Expression and Pathogenesis"],"prefix":"10.3389","volume":"9","author":[{"given":"Liya","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,11,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"927","DOI":"10.11817\/j.issn.1672-7347.2017.08.009","article-title":"Mortality trend of inpatients with connective tissue diseases: 2005-2014","volume":"42","author":"Li","year":"2017","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","article-title":"Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies","volume":"51","author":"Elhai","year":"2012","journal-title":"Rheumatology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jbspin.2014.10.010","article-title":"Systemic sclerosis: recent insights","volume":"82","author":"Elhai","year":"2015","journal-title":"Joint Bone Spine"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/nrrheum.2014.222","article-title":"Systemic sclerosis in 2014: advances in cohort enrichment shape future of trial design","volume":"11","author":"Allanore","year":"2015","journal-title":"Nat Rev Rheumatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/cmi.2016.34","article-title":"HMGB1, IL-1alpha, IL-33 and S100 proteins: dual-function alarmins","volume":"14","author":"Bertheloot","year":"2017","journal-title":"Cell Mol Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","article-title":"The interleukin-1 family: back to the future","volume":"39","author":"Garlanda","year":"2013","journal-title":"Immunity"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/j.1476-5381.2009.00331.x","article-title":"Dual functionality of interleukin-1 family cytokines: implications for anti-interleukin-1 therapy","volume":"157","author":"Luheshi","year":"2009","journal-title":"Br J Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0002-9440(10)63631-0","article-title":"Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules","volume":"163","author":"Baekkevold","year":"2003","journal-title":"Am J Pathol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1600-065X.2008.00701.x","article-title":"The interleukin-1 receptor\/Toll-like receptor superfamily: 10 years of progress","volume":"226","author":"O'Neill","year":"2008","journal-title":"Immunol Rev."},{"key":"B11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0014-5793(93)81333-U","article-title":"Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1","volume":"318","author":"Yanagisawa","year":"1993","journal-title":"FEBS Lett."},{"key":"B12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/imr.12619","article-title":"Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family","volume":"281","author":"Cayrol","year":"2018","journal-title":"Immunol Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1600-065X.2008.00624.x","article-title":"IL-1, IL-18, and IL-33 families of cytokines","volume":"223","author":"Arend","year":"2008","journal-title":"Immunol Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.immuni.2009.05.007","article-title":"Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases","volume":"31","author":"Luthi","year":"2009","journal-title":"Immunity"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1073\/pnas.1115884109","article-title":"IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G","volume":"109","author":"Lefrancais","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"key":"B16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1684\/ecn.2012.0320","article-title":"Mechanisms of IL-33 processing and secretion: differences and similarities between IL-1 family members","volume":"23","author":"Lefrancais","year":"2012","journal-title":"Eur Cytokine Netw."},{"key":"B17","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e3331","DOI":"10.1371\/journal.pone.0003331","article-title":"The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel \u2018alarmin\u2019?","volume":"3","author":"Moussion","year":"2008","journal-title":"PLoS ONE"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.2353\/ajpath.2008.080014","article-title":"Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation","volume":"173","author":"Kuchler","year":"2008","journal-title":"Am J Pathol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.4049\/jimmunol.1101977","article-title":"Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain","volume":"188","author":"Pichery","year":"2012","journal-title":"J Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/JIM.0000000000000213","article-title":"Red blood cells store and release interleukin-33","volume":"63","author":"Wei","year":"2015","journal-title":"J Investig Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1165\/rcmb.2013-0093OC","article-title":"Interleukin-33 potentiates bleomycin-induced lung injury","volume":"49","author":"Luzina","year":"2013","journal-title":"Am J Respir Cell Mol Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"8327","DOI":"10.1038\/ncomms9327","article-title":"Sleeman and T. mustelin: oxidation of the alarmin IL-33 regulates ST2-dependent inflammation","volume":"6","author":"Cohen","year":"2015","journal-title":"Nat Commun."},{"key":"B24","doi-asserted-by":"publisher","first-page":"9021","DOI":"10.1073\/pnas.0812690106","article-title":"The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1","volume":"106","author":"Cayrol","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1002\/eji.200940291","article-title":"Characterization of ST2 transgenic mice with resistance to IL-33","volume":"40","author":"Ohto-Ozaki","year":"2010","journal-title":"Eur J Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1164\/ajrccm.164.2.2008120","article-title":"Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation","volume":"164","author":"Oshikawa","year":"2001","journal-title":"Am J Respir Crit Care Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nri2692","article-title":"Disease-associated functions of IL-33: the new kid in the IL-1 family","volume":"10","author":"Liew","year":"2010","journal-title":"Nat Rev Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10165-011-0480-1","article-title":"Involvement of IL-33 in the pathogenesis of rheumatoid arthritis: the effect of etanercept on the serum levels of IL-33","volume":"22","author":"Kageyama","year":"2012","journal-title":"Mod Rheumatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3346\/jkms.2011.26.9.1132","article-title":"Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis","volume":"26","author":"Hong","year":"2011","journal-title":"J Korean Med Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1006\/bbrc.2001.5090","article-title":"Identification of human ST2 protein in the sera of patients with autoimmune diseases","volume":"284","author":"Kuroiwa","year":"2001","journal-title":"Biochem Biophys Res Commun."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.2310\/JIM.0b013e31826d8fcb","article-title":"IL-33: a potential therapeutic target in autoimmune diseases","volume":"60","author":"Wang","year":"2012","journal-title":"J Investig Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"603750","DOI":"10.1155\/2015\/603750","article-title":"Increased levels of soluble ST2 in patients with active newly diagnosed ANCA-associated vasculitis","volume":"2015","author":"Hladinova","year":"2015","journal-title":"Mediators Inflamm."},{"key":"B33","doi-asserted-by":"publisher","first-page":"42413","DOI":"10.1038\/srep42413","article-title":"Interleukin-33 produced by M2 macrophages and other immune cells contributes to Th2 immune reaction of IgG4-related disease","volume":"7","author":"Furukawa","year":"2017","journal-title":"Sci Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ajpath.2011.03.010","article-title":"The immune-modulating cytokine and endogenous Alarmin interleukin-33 is upregulated in skin exposed to inflammatory UVB radiation","volume":"179","author":"Byrne","year":"2011","journal-title":"Am J Pathol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"34255","DOI":"10.1038\/srep34255","article-title":"Extracellular IL-33 cytokine, but not endogenous nuclear IL-33, regulates protein expression in endothelial cells","volume":"6","author":"Gautier","year":"2016","journal-title":"Sci Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/imm.12174","article-title":"Emerging role of interleukin-33 in autoimmune diseases","volume":"141","author":"Pei","year":"2014","journal-title":"Immunology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrrheum.2011.149","article-title":"Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities","volume":"8","author":"Bhattacharyya","year":"2011","journal-title":"Nat Rev Rheumatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1172\/JCI31139","article-title":"Systemic sclerosis: a prototypic multisystem fibrotic disorder","volume":"117","author":"Varga","year":"2007","journal-title":"J Clin Invest."},{"key":"B39","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00393-016-0202-3","article-title":"Elevated serum levels of interleukin-1beta and interleukin-33 in patients with systemic sclerosis in Chinese population","volume":"77","author":"Zhang","year":"2016","journal-title":"Z Rheumatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1136\/annrheumdis-2012-201553","article-title":"Increased serum IL-33 levels may indicate vascular involvement in systemic sclerosis","volume":"72","author":"Terras","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10067-011-1686-5","article-title":"Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis","volume":"30","author":"Yanaba","year":"2011","journal-title":"Clin Rheumatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1136\/ard.2010.148247","article-title":"Increased circulating levels of interleukin 33 in systemic sclerosis correlate with early disease stage and microvascular involvement","volume":"70","author":"Manetti","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/sji.12317","article-title":"Increased serum levels of the IL-33 neutralizing sST2 in limited cutaneous systemic sclerosis","volume":"82","author":"Wagner","year":"2015","journal-title":"Scand J Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.autrev.2017.05.024","article-title":"The role of endothelial cells in the vasculopathy of systemic sclerosis: a systematic review","volume":"16","author":"Mostmans","year":"2017","journal-title":"Autoimmun Rev."},{"key":"B45","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s10875-014-0037-0","article-title":"Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels","volume":"34","author":"Vettori","year":"2014","journal-title":"J Clin Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1136\/ard.2009.119321","article-title":"The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis","volume":"69","author":"Manetti","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"6941","DOI":"10.1074\/jbc.M111.298703","article-title":"Interleukin 33 as a mechanically responsive cytokine secreted by living cells","volume":"287","author":"Kakkar","year":"2012","journal-title":"J Biol Chem."},{"key":"B48","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12890-017-0380-z","article-title":"Upregulation of interleukin-33 and thymic stromal lymphopoietin levels in the lungs of idiopathic pulmonary fibrosis","volume":"17","author":"Lee","year":"2017","journal-title":"BMC Pulm Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"403","DOI":"10.4049\/jimmunol.1200259","article-title":"Full-length IL-33 promotes inflammation but not Th2 response in vivo in an ST2-independent fashion","volume":"189","author":"Luzina","year":"2012","journal-title":"J Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.jaci.2014.05.011","article-title":"IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice","volume":"134","author":"Li","year":"2014","journal-title":"J Allergy Clin Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11926-012-0297-8","article-title":"The immune pathogenesis of scleroderma: context is everything","volume":"15","author":"Greenblatt","year":"2013","journal-title":"Curr Rheumatol Rep."},{"key":"B52","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/cge.12946","article-title":"Systematic approach to understanding the pathogenesis of systemic sclerosis","volume":"92","author":"Zuo","year":"2017","journal-title":"Clin Genet."},{"key":"B53","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00296-015-3417-8","article-title":"The IL-33 gene is related to increased susceptibility to systemic sclerosis","volume":"36","author":"Koca","year":"2016","journal-title":"Rheumatol Int."},{"key":"B54","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/nrrheum.2009.26","article-title":"Transforming growth factor beta as a therapeutic target in systemic sclerosis","volume":"5","author":"Varga","year":"2009","journal-title":"Nat Rev Rheumatol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/nm1663","article-title":"TLR4 enhances TGF-beta signaling and hepatic fibrosis","volume":"13","author":"Seki","year":"2007","journal-title":"Nat Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"G433","DOI":"10.1152\/ajpgi.00163.2009","article-title":"Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice","volume":"300","author":"Csak","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/art.23486","article-title":"Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis","volume":"58","author":"Kim","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B58","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.semarthrit.2015.06.006","article-title":"Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles","volume":"45","author":"Torok","year":"2015","journal-title":"Semin Arthritis Rheum."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.4049\/jimmunol.0903306","article-title":"IL-33 induces IL-13-dependent cutaneous fibrosis","volume":"184","author":"Rankin","year":"2010","journal-title":"J Immunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.4049\/jimmunol.0901575","article-title":"IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation","volume":"183","author":"Kurowska-Stolarska","year":"2009","journal-title":"J Immunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.bbrep.2016.02.002","article-title":"Soluble ST2 suppresses the effect of interleukin-33 on lung type 2 innate lymphoid cells","volume":"5","author":"Hayakawa","year":"2016","journal-title":"Biochem Biophys Rep."},{"key":"B62","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.immuni.2015.05.019","article-title":"Interleukin-33 and interferon-gamma counter-regulate group 2 innate lymphoid cell activation during immune perturbation","volume":"43","author":"Molofsky","year":"2015","journal-title":"Immunity"},{"key":"B63","doi-asserted-by":"publisher","first-page":"11829","DOI":"10.1074\/jbc.M113.534396","article-title":"IFN-gamma directly controls IL-33 protein level through a STAT1- and LMP2-dependent mechanism","volume":"289","author":"Kopach","year":"2014","journal-title":"J Biol Chem."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1002\/eji.201344310","article-title":"Serum amyloid A induces interleukin-33 expression through an IRF7-dependent pathway","volume":"44","author":"Sun","year":"2014","journal-title":"Eur J Immunol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/mi.2012.130","article-title":"Potential autocrine regulation of interleukin-33\/ST2 signaling of dendritic cells in allergic inflammation","volume":"6","author":"Su","year":"2013","journal-title":"Mucosal Immunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e1001762","DOI":"10.1371\/journal.pbio.1001762","article-title":"A20-deficient mast cells exacerbate inflammatory responses in vivo","volume":"12","author":"Heger","year":"2014","journal-title":"PLoS Biol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jaci.2014.06.013","article-title":"Signaling through FcRgamma-associated receptors on dendritic cells drives IL-33-dependent TH2-type responses","volume":"134","author":"Tjota","year":"2014","journal-title":"J Allergy Clin Immunol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.immuni.2015.06.006","article-title":"Interleukin-33 in Tissue Homeostasis, Injury, and Inflammation","volume":"42","author":"Molofsky","year":"2015","journal-title":"Immunity"},{"key":"B69","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/cmi.2010.3","article-title":"The enigmatic processing and secretion of interleukin-33","volume":"7","author":"Zhao","year":"2010","journal-title":"Cell Mol Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/JID.2015.406","article-title":"IL-33-dependent group 2 innate lymphoid cells promote cutaneous wound healing","volume":"136","author":"Rak","year":"2016","journal-title":"J Invest Dermatol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"e0128094","DOI":"10.1371\/journal.pone.0128094","article-title":"FOXP3+ T cells recruited to sites of sterile skeletal muscle injury regulate the fate of satellite cells and guide effective tissue regeneration","volume":"10","author":"Castiglioni","year":"2015","journal-title":"PLoS ONE"},{"key":"B72","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.immuni.2016.01.009","article-title":"Poor repair of skeletal muscle in aging mice reflects a defect in local, interleukin-33-dependent accumulation of regulatory T cells","volume":"44","author":"Kuswanto","year":"2016","journal-title":"Immunity"},{"key":"B73","doi-asserted-by":"publisher","first-page":"e0152163","DOI":"10.1371\/journal.pone.0152163","article-title":"TLR3 agonist poly-IC induces IL-33 and promotes myelin repair","volume":"11","author":"Natarajan","year":"2016","journal-title":"PLoS ONE"},{"key":"B74","doi-asserted-by":"publisher","first-page":"6774","DOI":"10.1038\/ncomms7774","article-title":"MicroRNA29a regulates IL-33-mediated tissue remodelling in tendon disease","volume":"6","author":"Millar","year":"2015","journal-title":"Nat Commun."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s12026-016-8797-7","article-title":"Association of interleukin-1 family cytokines single nucleotide polymorphisms with susceptibility to systemic sclerosis: an independent case-control study and a meta-analysis","volume":"64","author":"Huang","year":"2016","journal-title":"Immunol Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"R105","DOI":"10.1186\/ar4554","article-title":"Genetic variant in IL33 is associated with susceptibility to rheumatoid arthritis","volume":"16","author":"Li","year":"2014","journal-title":"Arthritis Res Ther."},{"key":"B77","doi-asserted-by":"publisher","first-page":"e0168828","DOI":"10.1371\/journal.pone.0168828","article-title":"The rs7044343 polymorphism of the interleukin 33 gene is associated with decreased risk of developing premature coronary artery disease and central obesity, and could be involved in regulating the production of IL-33","volume":"12","author":"Angeles-Martinez","year":"2017","journal-title":"PLoS ONE"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1042\/CS20170098","article-title":"Cytokines of the IL-1 family: recognized targets in chronic inflammation underrated in organ transplantations","volume":"131","author":"Stri","year":"2017","journal-title":"Clin Sci."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.cca.2012.06.021","article-title":"Comparison of plasma concentrations of soluble ST2 measured by three different commercially available assays: the MBL ST2 assay, the Presage ST2 Assay, and the R&D ST2 assay","volume":"413","author":"Mueller","year":"2012","journal-title":"Clin. Chim."},{"key":"B80","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1586\/erm.12.128","article-title":"The Presage \u00ae ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2","volume":"13","author":"Mueller","year":"2013","journal-title":"Expert Rev Mol Diagn."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02663\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T06:48:56Z","timestamp":1542264536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02663\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,15]]},"references-count":80,"alternative-id":["10.3389\/fimmu.2018.02663"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02663","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,15]]},"article-number":"2663"}}